Zacks Investment Research
29 Sept 2026, 13:46 UTC · 1h ago
Verdict
Headline takes no side. We score LH +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Labcorp's specialty testing areas, including oncology and neurology, delivered double-digit revenue growth during the first half of 2026.
Priced inanalysis of H1 2026 results
So whatThe higher tests-per-accession mix in these segments is expected to expand margins relative to routine testing.
More positive than 79% of claims this week
Labcorp's consumer business maintained double-digit growth supported by Labcorp OnDemand and Marker by Labcorp.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of H1 2026 results
More positive than 67% of claims this week
Labcorp has a market capitalization of $25.11 billion and an earnings yield of 5.9%.
Priced incurrent market data
So whatThe 220bps premium in earnings yield over the industry's 3.7% suggests the stock is trading at a valuation discount.
More positive than 46% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company is expanding in high-growth specialty markets and leveraging AI to strengthen productivity and margins.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−0.4%
Price flat so far
$308.46 vs $309.57 close before publication (Sep 28) · not market-adjusted
LH chart →
